Key result
HMG-CoA reductase inhibitors provide a dose-dependent reduction in total and low-density lipoprotein cholesterol levels of up to 30% and 40%, respectively.
Efforts to identify and treat individuals with elevated blood cholesterol levels have increased dramatically in recent years. The bile acid sequestrants (cholestyramine, colestipol) and nicotinic acid have been the mainstays of pharmacologic therapy for patients with phenotype(s) IIA and IIB hyperlipoproteinemia, but produce symptomatic side effects in a high percentage of patients. Clinical trials with a new class of cholesterol-lowering drugs, the HMG-CoA reductase inhibitors, have consistently demonstrated a dose-dependent reduction in total and low-density lipoprotein cholesterol levels of up to 30% and 40%, respectively. Symptomatic side effects requiring withdrawal of treatment have been uncommon, but the incidences of opacification of the ocular lens and hepatoxicity remain to be defined. Lovastatin is the first HMG-CoA reductase inhibitor commercially available in the United States. Its efficacy alone, and in combination with the bile acid sequestrants, is reviewed in this report.
No takes yet. Share an insight, caveat, or question.
Vidt et al. (1988) conducted a review in Hypercholesterolemia (phenotypes IIA and IIB hyperlipoproteinemia). HMG-CoA reductase inhibitors (Lovastatin) was evaluated on Reduction in total and low-density lipoprotein cholesterol levels. HMG-CoA reductase inhibitors provide a dose-dependent reduction in total and low-density lipoprotein cholesterol levels of up to 30% and 40%, respectively.
Synapse has enriched 5 related papers. Consider them for comparative context: